Picard Medical Receives NYSE American Acceptance of Compliance Plan
MWN-AI** Summary
Picard Medical, Inc. (NYSE American: PMI), the parent company of SynCardia Systems LLC, has successfully received acceptance from NYSE American for its compliance plan to meet the exchange’s continued listing standards. This announcement, made on July 27, 2026, assures stakeholders that Picard Medical can continue trading its shares under the ticker symbol "PMI" while it implements the strategic initiatives laid out in its plan. The company has until November 8, 2027, to achieve compliance, which will be monitored through periodic reviews.
Richard Fang, the Interim CEO, expressed satisfaction with the NYSE American's acceptance, indicating that this approval provides a clear pathway for the company’s ongoing efforts to strengthen both its financial and operational positions. Over the previous year, Picard Medical has focused on advancing its next-generation Emperor Total Artificial Heart platform and cementing its financial foundation, while simultaneously providing support to patients through its established SynCardia Total Artificial Heart technology.
The SynCardia Total Artificial Heart is notable for being the first artificial heart approved by both the U.S. FDA and Health Canada and remains the only commercially available artificial heart in North America. With over 2,100 implants across 27 countries, it is recognized as the most widely used and studied artificial heart worldwide.
Picard Medical's commitment to improving its financial status and expanding its strategic initiatives reflects a focus on long-term growth. As the company moves forward, it plans to keep stakeholders informed about its progress during the compliance period. The announcement serves as a hopeful update for shareholders and underscores the company’s efforts toward sustainable development and innovation in the medical device sector.
MWN-AI** Analysis
Picard Medical, Inc. (NYSE American: PMI) recently garnered attention following the NYSE American's acceptance of its compliance plan to meet continued listing standards. This positive development is pivotal for investors, as it provides the company with a critical runway until November 2027 to enhance its operational and financial framework.
With SynCardia Systems' Total Artificial Heart technology, Picard stands as a unique player in the medical device sector, addressing a significant market need for patients with end-stage heart failure. The FDA and Health Canada’s approval of their artificial heart positions them favorably against potential competitors. Their recent advances into the next-generation Emperor Total Artificial Heart platform appear promising and are essential for long-term viability.
From a financial perspective, the acceptance of the compliance plan is a declaration of resilience that could stabilize investor confidence. Investors should remain vigilant during this compliance period as Picard Medical works to turn around its operational hurdles. The ongoing efforts outlined by interim CEO Richard Fang showcase a commitment to regaining compliance, potentially indicative of strategic planning aimed at boosting shareholder value.
However, investors must also note the inherent risks. Compliance with listing standards and the successful development of new products are contingent upon several factors, including market dynamics and regulatory approvals, which could prove challenging. As such, it'll be vital to keep track of future updates from Picard Medical regarding their operational and financial health.
In conclusion, while the acceptance of the compliance plan allows for a period of adjustment and growth, it is imperative for investors to remain cautiously optimistic, continuously monitoring both the company's progress and the broader healthcare market landscape. Engaging with Picard Medical during this period could yield opportunities, yet due diligence remains essential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TUCSON, Ariz., July 27, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company” or “Picard Medical”), parent company of SynCardia Systems LLC, maker of the world’s first and only total artificial heart approved by both the U.S. FDA and Health Canada, today announced that the NYSE American LLC (“NYSE American”) has accepted the Company’s plan to regain compliance with the exchange’s continued listing standards under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.
The acceptance of the Company’s compliance plan allows Picard Medical to continue listing and trading its common stock on the NYSE American under the ticker symbol “PMI” while executing the operational, strategic, and financial initiatives outlined in its plan. The Company has been granted a compliance period through November 8, 2027, subject to periodic review by the NYSE American and continued compliance with all other applicable listing standards.
“We are pleased that the NYSE American has accepted our compliance plan, providing a clear path forward as we continue executing our long-term strategy,” said Richard Fang, Interim Chief Executive Officer of Picard Medical. “Over the past year, we have made meaningful progress across our business; from advancing our next-generation Emperor Total Artificial Heart platform to strengthening our financial position and continuing to support patients through our proven SynCardia Total Artificial Heart technology. We remain focused on building on this momentum, achieving compliance, and creating long-term value for our shareholders.”
The Company’s compliance plan reflects its commitment to strengthening its financial position while continuing to advance strategic initiatives that support long-term growth. Picard Medical will continue working closely with the NYSE American throughout the compliance period and expects to provide updates as appropriate.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.
Forward-looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on management’s current expectations, assumptions, and beliefs and involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Forward-looking statements can often be identified by words such as “anticipate,” “believe,” “continue,” “expect,” “goal,” “intend,” “may,” “plan,” “remain,” “target,” “will,” “advance,” “expand,” and similar expressions, and variations or negatives of these words.
These statements include, but are not limited to, statements regarding the Company’s financial condition, future operating results, commercialization activities, expectations for growth, expanding utilization of the SynCardia Total Artificial Heart, advancing development of the Emperor Total Artificial Heart and other next-generation technologies, capital raising activities, strengthening the Company’s commercial and financial position, strategic initiatives, and other statements that are not historical facts.
Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Factors that may cause such differences include, but are not limited to, risks relating to the Company’s ability to obtain additional financing, maintain compliance with applicable stock exchange listing requirements, achieve commercial adoption of its products, obtain regulatory approvals, execute manufacturing and supply chain initiatives, successfully develop next-generation technologies, manage market conditions, and other risks described in the Company’s filings with SEC.
The Company expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained herein, whether as a result of new information, future events, changed circumstances, or otherwise, except as required by law.
Additional information about the Company, including risk factors that may affect the Company’s business, financial condition, and results of operations, is contained in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available free of charge at www.sec.gov and on the Company’s investor relations website at www.picardmedical.com.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ**
What specific operational, strategic, and financial initiatives is Picard Medical Inc. (PMI) implementing to strengthen its compliance with NYSE American listing standards by November 8, 2027?
How does Picard Medical Inc. (PMI) plan to expand the commercialization of its SynCardia Total Artificial Heart technology amid growing competition in the medical devices sector?
What measures is Picard Medical Inc. (PMI) taking to ensure the successful development and commercialization of its next-generation Emperor Total Artificial Heart platform?
Given the importance of regulatory approvals, how is Picard Medical Inc. (PMI) preparing for potential challenges in obtaining necessary approvals for its new technologies and ensuring patient access to its products?
**MWN-AI FAQ is based on asking OpenAI questions about Picard Medical Inc. (NYSE: PMI).
NASDAQ: PMI
PMI Trading
7.21% G/L:
$9.37 Last:
792,505 Volume:
$8.70 Open:
PMI Latest News
